Shares of Xeris Pharmaceuticals Inc (XERS) soared 5.33% in the pre-market session on Friday, following analysts raising their price targets on the stock.
Piper Sandler raised its price target on Xeris Biopharma to $4 from $3, while maintaining a Neutral rating. H.C. Wainwright also boosted its price target to $8 from $6.60 and reiterated a Buy rating on the shares.
The positive analyst actions reflect optimism around Xeris Pharmaceuticals' prospects, driving the stock's significant upward movement during this morning's trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.